Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H28O3 |
Molecular Weight | 316.4345 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](C(O)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C
InChI
InChIKey=YQACAXHKQZCEOI-UDCWSGSHSA-N
InChI=1S/C20H28O3/c1-19-9-7-13(21)11-12(19)3-4-14-15-5-6-17(18(22)23)20(15,2)10-8-16(14)19/h11,14-17H,3-10H2,1-2H3,(H,22,23)/t14-,15-,16-,17+,19-,20-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6683842Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3783591
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6683842
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3783591
17β-Carboxyandrost-4-en-3-one is an intermediate in the synthesis of the drugs Dutasteride (D735000) and Finasteride. 17β-Carboxyandrost-4-en-3-one shows weak inhibition of Steroid 5-alpha-reductase and Androgen Receptor antagonism.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1856 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3783591 |
660.0 nM [IC50] | ||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3783591 |
8900.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6683842
1.5 mg/rat two times daily
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3783591
Human benign prostatic hypertrophy tissue that had been obtained by surgery and quickly frozen and stored at -70 "C served as the source of the enzyme. Typically, a 1.8-g portion was thawed, minced, and homogenized in 0.25 M sucrose buffer. The homogenate was centrifuged at 1200 rpm for 10 min, and the supernate was discarded. After the pellet was washed three times in buffer, it was suspended in buffer so that 1.0 mL contained about 300 mg of homogenized tissue. This suspension (0.1 mL) was incubated with 0.01 mL of inhibitor (2g, 17β-Carboxyandrost-4-en-3-one) and 0.1 mL of a mixture containing [3H]testosterone, unlabeled testosterone and dihydrotestosterone, glucose 6-phosphate, glucose-6-phosphate dehydrogenase, and NADP for 30 min at 37 "C. After the incubation, the steroids were extracted with 3.0 mL of ethyl acetate, and the organic phase was separated and evaporated under N2 This extract was spotted onto TLC plates. After the TLC plates were developed in ethyl acetate-cyclohexane (l:l), the [3H]DHT zone was scraped from the plate and counted.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
302-97-6
Created by
admin on Fri Dec 15 15:58:44 GMT 2023 , Edited by admin on Fri Dec 15 15:58:44 GMT 2023
|
PRIMARY | |||
|
99472
Created by
admin on Fri Dec 15 15:58:44 GMT 2023 , Edited by admin on Fri Dec 15 15:58:44 GMT 2023
|
PRIMARY | |||
|
6E3DV757KY
Created by
admin on Fri Dec 15 15:58:44 GMT 2023 , Edited by admin on Fri Dec 15 15:58:44 GMT 2023
|
PRIMARY | |||
|
DTXSID0057706
Created by
admin on Fri Dec 15 15:58:44 GMT 2023 , Edited by admin on Fri Dec 15 15:58:44 GMT 2023
|
PRIMARY | |||
|
226121
Created by
admin on Fri Dec 15 15:58:44 GMT 2023 , Edited by admin on Fri Dec 15 15:58:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY